Serina Therapeutics Soars 16.48% on Analyst Buy Rating

On July 15, 2025, Serina Therapeutics saw a significant rise of 16.48% in pre-market trading, reflecting strong investor interest and confidence in the company's prospects.

Serina Therapeutics is a clinical-stage biotechnology company focused on developing a pipeline of drug candidates to treat neurological diseases and other indications. The company's POZ Platform is designed to enhance the efficacy and safety profile of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs). The proprietary POZ technology utilizes a synthetic, water-soluble, low-viscosity polymer called poly(2-oxazoline), which allows for greater control in drug loading and precise release rates of attached drugs delivered via subcutaneous injection.

Serina Therapeutics' lead candidate, SER-252, is an investigational apomorphine therapy developed using the POZ platform. This therapy is designed to provide continuous dopaminergic stimulation, making it a promising treatment for advanced Parkinson's disease. The company's innovative approach to drug delivery has garnered attention from analysts, with HC Wainwright & Co. initiating coverage on Serina Therapeutics with a "Buy" rating and a price target of $15. This positive outlook from analysts has contributed to the recent surge in investor interest and stock performance.